 |
| Research Area: |
Smart Medical Systems and Technology |
| Principal Investigator: |
Lakshmi Putcha, Ph.D. |
| Organization: |
NASA-Johnson Space Center |
| Project Title: |
Microcapsule Gel Formulation of Promethazine Hydrochloride for Intranasal Administration |
| Funding Period: |
2001-2003 |
|
A continuing challenge for space medical operations at NASA is the
management of pathology associated with neurovestibular adaptation during
space flight. A primary manifestation of this problem, particularly in
the first few flight days of shuttle missions, is space motion sickness
(SMS). The current treatment of choice for symptoms associated with SMS
is promethazine (PMZ). Although oral tablets and rectal suppositories
have been used during space flights, the intramuscular route appears to be
most effective. On the other hand, intramuscular administration of drugs
is an invasive procedure and PMZ causes irritation at the site of
injection. A key research topic in the Smart Medical Systems area of the
NSBRI 99-02 research announcement is development of novel therapeutic
modalities for remote site medical operations such as space missions. In
response to this initiative, the goal of this research is to
develop an intranasal dosage formulation of PMZ that will provide
crewmembers with a non-invasive means of self-administering SMS
medications. Accordingly, the following three aims will be addressed:
- Develop a microencapsulated, pH-balanced gel dosage formulation and a
combination form with a corticosteroid for intranasal administration of
PMZ;
- Establish the release kinetics and shelf life of the optimized
dosage forms; and
- Assess bioavailability, nasal mucosal irritability
and toxicity of the selected dosage forms in rats.
The proposed formulation development will focus on tailoring the release
characteristics of the dosage form to optimize therapeutic index and
minimize irritability at the site of administration. Once the optimal
dosage form has been identified based on release kinetics and stability
characteristics, bioavailability, nasal irritability and toxicity after
single and multiple dose administration will be assessed in an animal
model. Development of an intranasal drug delivery system for motion
sickness treatment will benefit pharmacotherapeutics in space as well as
on Earth.
Project Description
|